Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, TVARDI THERAPEUTICS, INC. reported revenue of $7M, down 66.0% year over year. Operating margin was -393.8% and net margin -411.9%, on a free-cash-flow margin of -271.1% with capital expenditure at 14.7% of revenue. Every figure is computed directly from TVRD's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $7M | -393.8% | -411.9% |
| FY2023 | $21M | -579.4% | -565.2% |
| FY2022 | $42M | -209.1% | -204.2% |
| FY2021 | $23M | -386.8% | -384.1% |
| FY2020 | $135M | 4.0% | 6.2% |
How does TVRD compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.